Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges ; day:14 ; month:8 ; year:2020 ; pages:1-11
Heart failure reviews ; (14.8.2020), 1-11
- Urheber
-
Bruno, Marianna
Castaño, Adam
Burton, Arianna
Grodin, Justin L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10741-020-10010-8
- URN
-
urn:nbn:de:101:1-2020100718541512578591
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bruno, Marianna
- Castaño, Adam
- Burton, Arianna
- Grodin, Justin L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy in a Young Female
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan
Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy in a Young Female
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan
Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy in a Young Female
Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan